AnaptysBio Inc (NASDAQ:ANAB) – Equities researchers at SunTrust Banks dropped their FY2020 earnings per share estimates for shares of AnaptysBio in a research report issued to clients and investors on Sunday, June 23rd, Zacks Investment Research reports. SunTrust Banks analyst J. Lee now anticipates that the biotechnology company will post earnings of ($4.73) per share for the year, down from their prior estimate of ($4.58). SunTrust Banks has a “Buy” rating and a $93.00 price objective on the stock.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01.
A number of other research firms also recently issued reports on ANAB. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald boosted their price target on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Stifel Nicolaus downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating and reduced their price target for the company from $124.00 to $74.00 in a research note on Friday, June 21st. HC Wainwright set a $126.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Credit Suisse Group reduced their price target on shares of from GBX 145 ($1.89) to GBX 105 ($1.37) and set a “neutral” rating on the stock in a research note on Friday, June 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Buy” and a consensus price target of $111.25.
ANAB stock traded up $0.38 during trading on Wednesday, reaching $55.02. 160,621 shares of the stock were exchanged, compared to its average volume of 274,032. The stock has a 50 day simple moving average of $65.82. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -22.01 and a beta of 1.39. AnaptysBio has a 1 year low of $52.71 and a 1 year high of $110.00.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Diag Capital Management LP acquired a new position in AnaptysBio during the 4th quarter worth approximately $95,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of AnaptysBio in the 1st quarter valued at $110,000. SG Americas Securities LLC acquired a new position in shares of AnaptysBio in the 4th quarter valued at $126,000. Bank of America Corp DE boosted its holdings in shares of AnaptysBio by 141.2% in the 4th quarter. Bank of America Corp DE now owns 4,397 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 15,067 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in shares of AnaptysBio in the 1st quarter valued at $290,000.
In other AnaptysBio news, CEO Hamza Suria sold 22,428 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the transaction, the chief executive officer now owns 31,524 shares in the company, valued at approximately $2,325,210.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Marco Londei sold 10,060 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total transaction of $734,983.60. Following the transaction, the insider now owns 32,437 shares of the company’s stock, valued at approximately $2,369,847.22. The disclosure for this sale can be found here. Insiders own 14.00% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.